GlassScriptPhysician profile
Kristin A Taniguchi
NPI 1477136307
$6,131.62
in general payments reported to CMS, 2019-2025
31 companies · $2,198 in 2025
The $2,198 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,462 · 2024: $2,472 · 2025: $2,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,772 · Consulting Fee: $275 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,771.63 |
| Consulting Fee | $275.00 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,087.84 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $832.09 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $628.23 | 2023-2025 | |
| Lilly USA, LLC | $485.49 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $420.37 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $342.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Baxter Healthcare | $275.00 | 2025 | |
| Amgen INC. | $231.38 | 2023-2025 | Evenity, Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $195.35 | 2023 | Quviviq |
| Astellas Pharma US INC | $184.67 | 2023-2025 | Veozah |
| Gilead Sciences, INC. | $158.51 | 2024-2025 | Yeztugo |
| Axsome Therapeutics, INC. | $150.67 | 2023-2025 | Auvelity |
| Optinose US, INC. | $139.49 | 2025 | |
| Sanofi-Aventis U.S. LLC | $138.78 | 2024-2025 | |
| Pfizer INC. | $118.82 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $101.24 | 2024 | Valtoco |
| Lundbeck LLC | $95.93 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $90.80 | 2025 | Gemtesa |
| Abbott Laboratories | $84.84 | 2024-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $51.79 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.08 | 2024 | Jardiance |
| Seqirus USA INC | $38.09 | 2023-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| E.R. Squibb & Sons, L.L.C. | $37.89 | 2023-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $33.68 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $30.19 | 2023 | Xarelto |
| Renalytix Ai, INC. | $29.53 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Phathom Pharmaceuticals, INC. | $25.90 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.21 | 2024 | Xifaxan |
| Dexcom, INC. | $21.85 | 2024 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $14.90 | 2025 | Tirosint, Licart, Flector |
| Merck Sharp & Dohme LLC | $14.19 | 2023 | Verquvo, Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Taniguchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.